Pharmaceutical companies search for IRA response as they brace for drug pricing talks
BioPharma
Stay updated with breaking news from David Ricks. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eli Lilly is investing in hundreds of projects focused on AI, machine learning, and automation.
Eli Lilly And Co (NYSE: LLY) CEO David Ricks voiced his concerns about the potential impact of Medicare price negotiations on drug development, which aim to reduce costs for older Americans. In an interview on CNBC's "The Exchange," Ricks said, "I'm really worried about the harm this will do to new cures and possibilities in medicine." Ricks specifically referred to a provision in the Inflation Reduction Act, proposed by the Biden administration, which empowers the Medicare program to negotiate
Eli Lilly And Co (NYSE: LLY) CEO David Ricks voiced his concerns about the potential impact of Medicare price negotiations on drug development, which aim to reduce costs for older Americans.